AbbVie and Genmab's Epkinly (epcoritamab-bysp) Receives the US FDA’s Approval for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Shots:
- The US FDA has approved Epkinly for adult patients with r/r DLBCL. The therapy is being co-developed by AbbVie & Genmab
- The approval was based on the P-I/II trial (EPCORE NHL-1) evaluating epcoritamab (SC) in patients with r/r B-cell lymphoma. The results showed ORR (61%) with CR (38%) and PR (23%), and m-DoR was 15.6mos. after a median follow-up of 9.8mos., 82% of patients had disease refractory to the last therapy & 29% were refractory to CAR T-cell therapy. The safety profile was consistent with prior studies
- Epkinly, an IgG1-bispecific Ab developed using Genmab's DuoBody technology. Both companies will share commercial responsibilities in the US & Japan while AbbVie responsible for further global commercialization
Ref: AbbVie | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
